Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ:
VERO), a global medical aesthetic technology leader, announced
financial results for the three and nine months ended September 30,
2022.
Third Quarter 2022 Summary &
Operating Highlights:
- Total revenue of $21.5 million,
down $3.0 million, or 12%, year-over-year.
- U.S. revenue down 4%
year-over-year.
- Cash system revenue up 30%
year-over-year, representing approximately 59% of total systems and
subscriptions revenue, compared to 39% in the prior year
period.
- GAAP net loss attributable to
stockholders of $14.6 million, compared to GAAP net loss
attributable to stockholders of $9.8 million last year.
- Adjusted EBITDA loss of $7.7
million, compared to Adjusted EBITDA loss of $3.5 million last
year.
- On October 3, 2022, the Company
announced that Rajiv De Silva has been appointed as the Company’s
Chief Executive Officer and a member of the Board of Directors,
effective October 2, 2022.
- On October 11, 2022, the Company
announced the appointment of Dr. Hemanth Varghese to the position
of President & Chief Business Officer, effective October 17,
2022.
Management Commentary:
“Venus Concept delivered third quarter revenue
results that were in line with the preliminary revenue expectations
provided on October 3rd,” said Rajiv De Silva, Chief Executive
Officer of Venus Concept. “While revenue declined on a
year-over-year basis in Q3, our strategic initiative to prioritize
cash systems sales resulted in a notably higher mix of cash system
sales and stronger cash flow from the sale of our
highly-differentiated technologies, compared to the prior year
period. We also made progress on our strategic initiative to
optimize our international operations including closing
underperforming direct sales offices in countries which are not
anticipated to produce sustainable results. The organization
remains highly focused on our key strategic initiatives to further
enhance the cash flow profile of our business and to accelerate our
path to long-term, sustainable, profitability.”
Third Quarter and First Nine Months of
2022 Revenue by Region and by Product Type:
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
|
|
(dollars in thousands) |
|
|
(dollars in thousands) |
|
Revenues by region: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
United States |
|
$ |
11,774 |
|
|
$ |
12,259 |
|
|
$ |
38,319 |
|
|
$ |
35,345 |
|
International |
|
|
9,765 |
|
|
|
12,304 |
|
|
|
36,892 |
|
|
|
37,643 |
|
Total revenue |
|
$ |
21,539 |
|
|
$ |
24,563 |
|
|
$ |
75,211 |
|
|
$ |
72,988 |
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
|
|
(dollars in thousands) |
|
|
(dollars in thousands) |
|
Revenues by product: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subscription—Systems |
|
$ |
7,193 |
|
|
$ |
12,634 |
|
|
$ |
29,490 |
|
|
$ |
33,958 |
|
Products—Systems |
|
|
10,416 |
|
|
|
8,022 |
|
|
|
33,838 |
|
|
|
26,526 |
|
Products—Other (1) |
|
|
3,125 |
|
|
|
2,961 |
|
|
|
9,702 |
|
|
|
9,330 |
|
Services (2) |
|
|
805 |
|
|
|
946 |
|
|
|
2,181 |
|
|
|
3,174 |
|
Total revenue |
|
$ |
21,539 |
|
|
$ |
24,563 |
|
|
$ |
75,211 |
|
|
$ |
72,988 |
|
(1) |
Products-Other include ARTAS procedure kits and other
consumables. |
(2) |
Services include extended warranty sales and VeroGrafters
technician services. VeroGrafters technician services were
discontinued in the fourth quarter of 2021. |
Third Quarter 2022 Financial Results:
|
|
Three Months Ended September 30, |
|
|
|
|
|
|
|
|
|
|
|
2022 |
|
|
2021 |
|
|
Change |
|
(in thousands, except
percentages) |
|
$ |
|
|
% of Total |
|
|
$ |
|
|
% of Total |
|
|
$ |
|
|
% |
|
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subscription—Systems |
|
$ |
7,193 |
|
|
33.4 |
|
|
$ |
12,634 |
|
|
|
51.4 |
|
|
$ |
(5,441 |
) |
|
|
(43.1 |
) |
Products—Systems |
|
|
10,416 |
|
|
48.4 |
|
|
|
8,022 |
|
|
|
32.6 |
|
|
|
2,394 |
|
|
|
29.8 |
|
Products—Other |
|
|
3,125 |
|
|
14.5 |
|
|
|
2,961 |
|
|
|
12.1 |
|
|
|
164 |
|
|
|
5.5 |
|
Services |
|
|
805 |
|
|
3.7 |
|
|
|
946 |
|
|
|
3.9 |
|
|
|
(141 |
) |
|
|
(14.9 |
) |
Total |
|
$ |
21,539 |
|
|
100.0 |
|
|
$ |
24,563 |
|
|
|
100.0 |
|
|
$ |
(3,024 |
) |
|
|
(12.3 |
) |
Total revenue for the third quarter of 2022
decreased $3.0 million, or 12.3%, to $21.5 million, compared to the
third quarter of 2021. The decrease in total revenue, by region,
was driven by a 21% decrease year-over-year in international
revenue and a 4% decrease year-over-year in United States revenue.
Excluding the impact of changes in foreign currency exchange rates
versus the U.S. dollar, total revenue and international revenue, on
a constant currency basis, decreased 9% and 15%, respectively,
compared to the third quarter of 2021. The decrease in total
revenue, by product category, was driven by a 43% decrease in lease
revenue and a 15% decrease in services revenue, offset partially by
a 30% increase in systems revenue and a 6% increase in products
revenue. The percentage of total systems revenue derived from the
Company’s subscription model was approximately 41% in the third
quarter of 2022, compared to 61% in the prior year period.
Gross profit for the third quarter of 2022
decreased $3.9 million, or 23%, to $13.4 million compared to the
third quarter of 2021. Gross margin was 62.1%, compared to 70.5% of
revenue for the third quarter of 2021. The change in gross margin
was driven primarily by the year-over-year decline in revenue as
well as a $1.4 million write-down of end-of-life devices and parts
inventory, and a $0.8 million impact from changes in foreign
currencies which depreciated relative to the U.S. dollar in the
period.
Operating expenses for the third quarter of 2022
increased $2.1 million, or 9%, to $24.8 million, compared to the
third quarter of 2021. The change in total operating expenses was
driven by an increase of $2.1 million, or 18%, in general and
administrative expenses and an increase of $0.6 million, or 33%, in
research and development expenses, offset partially by a decrease
of $0.7 million, or 8%, in sales and marketing expenses. Third
quarter of 2022 general and administrative expenses include
approximately $0.7 million of severance payments associated with a
workforce reduction in Venus Spain and Venus Canada. For the three
months ended September 30, 2021, general and administrative
expenses included loss on the sale of a subsidiary in South Africa
of approximately $0.2 million.
Operating loss for the third quarter of 2022 was
$11.4 million, compared to operating loss of $5.4 million for the
third quarter of 2021.
Net loss attributable to stockholders for the
third quarter of 2022 was $14.6 million, or $0.22 per share,
compared to net loss of $9.8 million for the third quarter of 2021.
Adjusted EBITDA loss for the third quarter of 2022 was $7.7
million, compared to adjusted EBITDA loss of $3.5 million for the
third quarter of 2021.
As of September 30, 2022, the Company had cash
and cash equivalents of $6.8 million and total debt obligations of
approximately $77.6 million, compared to $30.9 million and $77.3
million, respectively, as of December 31, 2021.
First Nine Months of 2022 Financial
Results:
|
|
Nine Months Ended September 30, |
|
|
|
|
|
|
|
|
|
|
|
2022 |
|
|
2021 |
|
|
Change |
|
(in thousands, except
percentages) |
|
$ |
|
|
% of Total |
|
|
$ |
|
|
% of Total |
|
|
$ |
|
|
% |
|
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subscription—Systems |
|
$ |
29,490 |
|
|
|
39.2 |
|
|
$ |
33,958 |
|
|
|
46.5 |
|
|
$ |
(4,468 |
) |
|
|
(13.2 |
) |
Products—Systems |
|
|
33,838 |
|
|
|
45.0 |
|
|
|
26,526 |
|
|
|
36.4 |
|
|
|
7,312 |
|
|
|
27.6 |
|
Products—Other |
|
|
9,702 |
|
|
|
12.9 |
|
|
|
9,330 |
|
|
|
12.8 |
|
|
|
372 |
|
|
|
4.0 |
|
Services |
|
|
2,181 |
|
|
|
2.9 |
|
|
|
3,174 |
|
|
|
4.3 |
|
|
|
(993 |
) |
|
|
(31.3 |
) |
Total |
|
$ |
75,211 |
|
|
|
100.0 |
|
|
$ |
72,988 |
|
|
|
100.0 |
|
|
$ |
2,223 |
|
|
|
3.0 |
|
Total revenue for the nine months ended September 30, 2022,
increased $2.2 million, or 3%, to $75.2 million. The increase in
total revenue, by region, was driven by an 8% increase in United
States revenue and a 2% decrease in international revenue.
Excluding the impact of changes in foreign currency exchanges rates
versus the U.S. dollar, total revenue and international revenue, on
a constant currency basis, increased 6% and 3%, respectively,
compared to the nine months ended September 30, 2021. The increase
in total revenue, by product category, was driven by a 28% increase
in systems revenue and a 4% increase in products revenue, offset
partially by a 13% decrease in lease revenue and a 31% decrease in
services revenue. The percentage of total systems revenue derived
from our subscription model was approximately 47%, compared to
approximately 56% for the nine months ended September 30, 2021.
Net loss attributable to stockholders for the
nine months ended September 30, 2022 decreased $15.1 million, or
81%, to $33.8 million, or $0.52 per share. Adjusted EBITDA loss for
the nine months ended September 30, 2022 decreased $10.9 million,
or 134%, to $19.0 million.
Conference Call Details:
Management will host a conference call at 5:00
p.m. Eastern Time on November 10, 2022, to discuss the results of
the quarter with a question and answer session. Those who would
like to participate may dial 877-407-2991 (201-389-0925 for
international callers) and provide access code 13733044. A live
webcast of the call will also be provided on the investor relations
section of the Company's website at ir.venusconcept.com.
For those unable to participate, a replay of the
call will be available for two weeks at 877-660-6853 (201-612-7415
for international callers); access code 13733044. The webcast will
be archived at ir.venusconcept.com.
About Venus Concept
Venus Concept is an innovative global medical
aesthetic technology leader with a broad product portfolio of
minimally invasive and non-invasive medical aesthetic and hair
restoration technologies and reach in over 60 countries and 18
direct markets. Venus Concept’s product portfolio consists of
aesthetic device platforms, including Venus Versa, Venus Legacy,
Venus Velocity, Venus Fiore, Venus Viva, Venus Glow, Venus Bliss,
Venus BlissMAX, Venus Epileve and Venus Viva MD. Venus Concept’s
hair restoration systems include NeoGraft® and the ARTAS® and ARTAS
iX® Robotic Hair Restoration systems. Venus Concept has been backed
by leading healthcare industry growth equity investors including EW
Healthcare Partners (formerly Essex Woodlands), HealthQuest
Capital, Longitude Capital Management, Aperture Venture Partners,
and Masters Special Situations.
Cautionary Statement Regarding
Forward-Looking Statements
This communication contains contains
“forward-looking” statements within the meaning of Section 27A
of the Securities Act of 1933, as amended and Section 21E of
the Securities Exchange Act of 1934, as amended. Any statements
contained herein that are not of historical facts may be deemed to
be forward-looking statements. In some cases, you can identify
these statements by words such as such as “anticipates,”
“believes,” “plans,” “expects,” “projects,” “future,” “intends,”
“may,” “should,” “could,” “estimates,” “predicts,” “potential,”
“continue,” “guidance,” and other similar expressions that are
predictions of or indicate future events and future trends. These
forward-looking statements include, but are not limited to,
statements about our financial performance; the growth in demand
for our systems and other products; and general economic
conditions, including the global economic impact of COVID-19, and
involve risks and uncertainties that may cause results to differ
materially from those set forth in the statements. These
forward-looking statements are based on current expectations,
estimates, forecasts, and projections about our business and the
industry in which the Company operates and management's beliefs and
assumptions and are not guarantees of future performance or
developments and involve known and unknown risks, uncertainties,
and other factors that are in some cases beyond our control. As a
result, any or all of our forward-looking statements in this
communication may turn out to be inaccurate. Factors that could
materially affect our business operations and financial performance
and condition include, but are not limited to, those risks and
uncertainties described under Part II Item 1A—“Risk Factors” in our
Quarterly Reports on Form 10-Q and Part I Item 1A—“Risk Factors” in
our Annual Report on Form 10-K for the fiscal year ended
December 31, 2021. You are urged to consider these factors
carefully in evaluating the forward-looking statements and are
cautioned not to place undue reliance on the forward-looking
statements. The forward-looking statements are based on information
available to us as of the date of this communication. Unless
required by law, the Company does not intend to publicly update or
revise any forward-looking statements to reflect new information or
future events or otherwise.
Venus Concept
Inc.Condensed Consolidated Balance
Sheets(Unaudited)
(In thousands of U.S. dollars, except
share and per share data)
|
|
September 30, |
|
|
December 31, |
|
|
|
2022 |
|
|
2021 |
|
ASSETS |
|
|
|
|
|
|
|
|
CURRENT ASSETS: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
6,777 |
|
|
$ |
30,876 |
|
Accounts receivable, net of allowance of $13,102 and $11,997 as of
September 30, 2022, and December 31, 2021, respectively |
|
|
40,876 |
|
|
|
46,918 |
|
Inventories |
|
|
24,241 |
|
|
|
20,543 |
|
Prepaid expenses |
|
|
1,912 |
|
|
|
2,737 |
|
Advances to suppliers |
|
|
3,605 |
|
|
|
2,162 |
|
Other current assets |
|
|
3,351 |
|
|
|
3,758 |
|
Total current assets |
|
|
80,762 |
|
|
|
106,994 |
|
LONG-TERM ASSETS: |
|
|
|
|
|
|
|
|
Long-term receivables |
|
|
23,253 |
|
|
|
27,710 |
|
Deferred tax assets |
|
|
912 |
|
|
|
284 |
|
Severance pay funds |
|
|
724 |
|
|
|
817 |
|
Property and equipment,
net |
|
|
2,180 |
|
|
|
2,669 |
|
Intangible assets |
|
|
12,795 |
|
|
|
15,393 |
|
Total long-term assets |
|
|
39,864 |
|
|
|
46,873 |
|
TOTAL ASSETS |
|
$ |
120,626 |
|
|
$ |
153,867 |
|
LIABILITIES AND
STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
|
|
CURRENT LIABILITIES: |
|
|
|
|
|
|
|
|
Trade payables |
|
$ |
6,093 |
|
|
$ |
4,913 |
|
Accrued expenses and other current liabilities |
|
|
17,335 |
|
|
|
19,512 |
|
Income taxes payable |
|
|
827 |
|
|
|
294 |
|
Unearned interest income |
|
|
2,575 |
|
|
|
2,678 |
|
Warranty accrual |
|
|
1,147 |
|
|
|
1,245 |
|
Deferred revenues |
|
|
1,535 |
|
|
|
2,030 |
|
Current portion of government assistance loans |
|
|
— |
|
|
|
543 |
|
Total current liabilities |
|
|
29,512 |
|
|
|
31,215 |
|
LONG-TERM LIABILITIES: |
|
|
|
|
|
|
|
|
Long-term debt |
|
|
77,616 |
|
|
|
77,325 |
|
Income tax payable |
|
|
592 |
|
|
|
563 |
|
Accrued severance pay |
|
|
845 |
|
|
|
911 |
|
Deferred tax liabilities |
|
|
54 |
|
|
|
46 |
|
Unearned interest income |
|
|
1,355 |
|
|
|
1,355 |
|
Warranty accrual |
|
|
426 |
|
|
|
508 |
|
Other long-term
liabilities |
|
|
213 |
|
|
|
348 |
|
Total long-term liabilities |
|
|
81,101 |
|
|
|
81,056 |
|
TOTAL LIABILITIES |
|
|
110,613 |
|
|
|
112,271 |
|
Commitments and Contingencies
(Note 8) |
|
|
|
|
|
|
|
|
STOCKHOLDERS’ EQUITY: |
|
|
|
|
|
|
|
|
Common Stock, $0.0001 par
value: 300,000,000 shares authorized as of September 30, 2022 and
December 31, 2021; 65,584,573 and 63,982,580 issued and outstanding
as of September 30, 2022, and December 31, 2021, respectively |
|
|
27 |
|
|
|
27 |
|
Additional paid-in
capital |
|
|
223,506 |
|
|
|
221,321 |
|
Accumulated deficit |
|
|
(214,188 |
) |
|
|
(180,405 |
) |
TOTAL STOCKHOLDERS’
EQUITY |
|
|
9,345 |
|
|
|
40,943 |
|
Non-controlling interests |
|
|
668 |
|
|
|
653 |
|
|
|
|
10,013 |
|
|
|
41,596 |
|
TOTAL LIABILITIES AND
STOCKHOLDERS’ EQUITY |
|
$ |
120,626 |
|
|
$ |
153,867 |
|
Venus Concept
Inc.Condensed Consolidated Statements of
Operations(Unaudited)(In
thousands of U.S. dollars, except per share data)
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Leases |
|
$ |
7,193 |
|
|
$ |
12,634 |
|
|
$ |
29,490 |
|
|
$ |
33,958 |
|
Products and services |
|
|
14,346 |
|
|
|
11,929 |
|
|
|
45,721 |
|
|
|
39,030 |
|
|
|
|
21,539 |
|
|
|
24,563 |
|
|
|
75,211 |
|
|
|
72,988 |
|
Cost of goods sold |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Leases |
|
|
2,608 |
|
|
|
2,938 |
|
|
|
8,069 |
|
|
|
7,444 |
|
Products and services |
|
|
5,558 |
|
|
|
4,319 |
|
|
|
16,960 |
|
|
|
14,287 |
|
|
|
|
8,166 |
|
|
|
7,257 |
|
|
|
25,029 |
|
|
|
21,731 |
|
Gross profit |
|
|
13,373 |
|
|
|
17,306 |
|
|
|
50,182 |
|
|
|
51,257 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sales and marketing |
|
|
8,094 |
|
|
|
8,775 |
|
|
|
27,484 |
|
|
|
26,743 |
|
General and administrative |
|
|
14,128 |
|
|
|
11,990 |
|
|
|
41,471 |
|
|
|
31,983 |
|
Research and development |
|
|
2,576 |
|
|
|
1,930 |
|
|
|
7,214 |
|
|
|
6,005 |
|
Gain on forgiveness of government assistance loans |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(2,775 |
) |
Total operating expenses |
|
|
24,798 |
|
|
|
22,695 |
|
|
|
76,169 |
|
|
|
61,956 |
|
Loss from operations |
|
|
(11,425 |
) |
|
|
(5,389 |
) |
|
|
(25,987 |
) |
|
|
(10,699 |
) |
Other expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign exchange loss |
|
|
2,014 |
|
|
|
1,645 |
|
|
|
4,389 |
|
|
|
2,489 |
|
Finance expenses |
|
|
1,219 |
|
|
|
1,000 |
|
|
|
3,176 |
|
|
|
4,046 |
|
Loss on disposal of subsidiaries |
|
|
— |
|
|
|
188 |
|
|
|
— |
|
|
|
188 |
|
Loss before income taxes |
|
|
(14,658 |
) |
|
|
(8,222 |
) |
|
|
(33,552 |
) |
|
|
(17,422 |
) |
Income tax (benefit)
expense |
|
|
(162 |
) |
|
|
616 |
|
|
|
92 |
|
|
|
609 |
|
Net loss |
|
|
(14,496 |
) |
|
|
(8,838 |
) |
|
|
(33,644 |
) |
|
|
(18,031 |
) |
Net loss attributable to
stockholders of the Company |
|
|
(14,605 |
) |
|
|
(9,798 |
) |
|
|
(33,783 |
) |
|
|
(18,680 |
) |
Net income attributable to
non-controlling interest |
|
|
109 |
|
|
|
960 |
|
|
|
139 |
|
|
|
649 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
$ |
(0.22 |
) |
|
$ |
(0.18 |
) |
|
$ |
(0.52 |
) |
|
$ |
(0.35 |
) |
Diluted |
|
$ |
(0.22 |
) |
|
$ |
(0.18 |
) |
|
$ |
(0.52 |
) |
|
$ |
(0.35 |
) |
Weighted-average number of
shares used in per share calculation: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
|
65,255 |
|
|
|
54,145 |
|
|
|
64,462 |
|
|
|
53,994 |
|
Diluted |
|
|
65,255 |
|
|
|
54,145 |
|
|
|
64,462 |
|
|
|
53,994 |
|
Venus Concept
Inc.Condensed Consolidated Statements of Cash
Flows(Unaudited)(in
thousands)
|
|
Nine Months Ended September 30, |
|
|
|
2022 |
|
|
2021 |
|
CASH FLOWS FROM OPERATING ACTIVITIES: |
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(33,644 |
) |
|
$ |
(18,031 |
) |
Adjustments to reconcile net loss to net cash used in operating
activities: |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
3,293 |
|
|
|
3,756 |
|
Stock-based compensation |
|
|
1,552 |
|
|
|
1,602 |
|
Provision (recovery) for bad debt |
|
|
5,912 |
|
|
|
(628 |
) |
Provision for inventory obsolescence |
|
|
1,753 |
|
|
|
1,107 |
|
Finance expenses and accretion |
|
|
291 |
|
|
|
981 |
|
Deferred tax recovery |
|
|
(620 |
) |
|
|
(666 |
) |
Loss on disposal of subsidiary |
|
|
— |
|
|
|
188 |
|
Gain on forgiveness of government assistance loans |
|
|
— |
|
|
|
(2,775 |
) |
Loss on disposal of property and equipment |
|
|
82 |
|
|
|
— |
|
Changes in operating assets
and liabilities: |
|
|
|
|
|
|
|
|
Accounts receivable short and long-term |
|
|
4,493 |
|
|
|
3,468 |
|
Inventories |
|
|
(5,451 |
) |
|
|
(4,373 |
) |
Prepaid expenses |
|
|
825 |
|
|
|
(112 |
) |
Advances to suppliers |
|
|
(1,443 |
) |
|
|
(142 |
) |
Other current assets |
|
|
407 |
|
|
|
909 |
|
Other long-term assets |
|
|
327 |
|
|
|
(102 |
) |
Trade payables |
|
|
1,180 |
|
|
|
(1,573 |
) |
Accrued expenses and other current liabilities |
|
|
(2,237 |
) |
|
|
(3,135 |
) |
Severance pay funds |
|
|
93 |
|
|
|
(58 |
) |
Unearned interest income |
|
|
(103 |
) |
|
|
127 |
|
Other long-term liabilities |
|
|
(283 |
) |
|
|
87 |
|
Net cash used in operating activities |
|
|
(23,573 |
) |
|
|
(19,370 |
) |
CASH FLOWS FROM
INVESTING ACTIVITIES: |
|
|
|
|
|
|
|
|
Purchases of property and equipment |
|
|
(297 |
) |
|
|
(194 |
) |
Cash received from sale of subsidiary, net of cash
relinquished |
|
|
— |
|
|
|
(40 |
) |
Net cash used in investing activities |
|
|
(297 |
) |
|
|
(234 |
) |
CASH FLOWS FROM
FINANCING ACTIVITIES: |
|
|
|
|
|
|
|
|
Proceeds from issuance of common stock, net of costs |
|
|
415 |
|
|
|
— |
|
Exercises of 2020 December Public Offering Warrants |
|
|
— |
|
|
|
903 |
|
Payment of earn-out liability |
|
|
— |
|
|
|
(147 |
) |
Repayment of government assistance loans |
|
|
(543 |
) |
|
|
— |
|
Proceeds from exercise of options |
|
|
23 |
|
|
|
332 |
|
Dividends from subsidiaries paid to non-controlling interest |
|
|
(124 |
) |
|
|
— |
|
Net cash (used in) provided by financing activities |
|
|
(229 |
) |
|
|
1,088 |
|
NET DECREASE IN CASH AND CASH
EQUIVALENTS AND RESTRICTED CASH |
|
|
(24,099 |
) |
|
|
(18,516 |
) |
CASH AND CASH EQUIVALENTS AND
RESTRICTED CASH — Beginning of period |
|
|
30,876 |
|
|
|
34,380 |
|
CASH AND CASH EQUIVALENTS AND
RESTRICTED CASH — End of period |
|
$ |
6,777 |
|
|
$ |
15,864 |
|
SUPPLEMENTAL
DISCLOSURES OF CASH FLOW INFORMATION: |
|
|
|
|
|
|
|
|
Cash paid for income taxes |
|
$ |
152 |
|
|
$ |
120 |
|
Cash paid for interest |
|
$ |
2,885 |
|
|
$ |
2,852 |
|
FINANCING
INFORMATION: |
|
|
|
|
|
|
|
|
Common stock issuance costs |
|
$ |
438 |
|
|
|
— |
|
Use of Non-GAAP Financial Measures
Adjusted EBITDA is a non-GAAP measure defined as net income
(loss) before foreign exchange loss (gain), financial expenses,
income tax expense (benefit), depreciation and amortization,
stock-based compensation and non-recurring items for a given
period. Adjusted EBITDA is not a measure of our financial
performance under U.S. GAAP and should not be considered an
alternative to net income or any other performance measures derived
in accordance with U.S. GAAP. Accordingly, you should consider
Adjusted EBITDA along with other financial performance measures,
including net income, and our financial results presented in
accordance with U.S. GAAP. Other companies, including companies in
our industry, may calculate Adjusted EBITDA differently or not at
all, which reduces its usefulness as a comparative measure. We
understand that although Adjusted EBITDA is frequently used by
securities analysts, lenders and others in their evaluation of
companies, Adjusted EBITDA has limitations as an analytical tool,
and you should not consider it in isolation, or as a substitute for
analysis of our results as reported under U.S. GAAP. Some of these
limitations are: Adjusted EBITDA does not reflect our cash
expenditures or future requirements for capital expenditures or
contractual commitments; Adjusted EBITDA does not reflect changes
in, or cash requirements for, our working capital needs; and
although depreciation and amortization are non-cash charges, the
assets being depreciated will often have to be replaced in the
future, and Adjusted EBITDA does not reflect any cash requirements
for such replacements.
We believe that Adjusted EBITDA is a useful measure for
analyzing the performance of our core business because it
facilitates operating performance comparisons from period to period
and company to company by backing out potential differences caused
by changes in foreign exchange rates that impact financial assets
and liabilities denominated in currencies other than the U.S.
dollar, tax positions (such as the impact on periods or companies
of changes in effective tax rates), the age and book depreciation
of fixed assets (affecting relative depreciation expense),
amortization of intangible assets, stock-based compensation expense
(because it is a non-cash expense) and non-recurring items as
explained below.
The following reconciliation of net (loss) income to Adjusted
EBITDA for the periods presented:
Venus Concept
Inc.Reconciliation of Net
Loss to Non-GAAP Adjusted EBITDA
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
Reconciliation of net
loss to adjusted EBITDA |
|
(in thousands) |
|
|
(in thousands) |
|
Net loss |
|
$ |
(14,496 |
) |
|
$ |
(8,838 |
) |
|
$ |
(33,644 |
) |
|
$ |
(18,031 |
) |
Foreign exchange loss |
|
|
2,014 |
|
|
|
1,645 |
|
|
|
4,389 |
|
|
|
2,489 |
|
Finance expenses |
|
|
1,219 |
|
|
|
1,000 |
|
|
|
3,176 |
|
|
|
4,046 |
|
Income tax (benefit)
expense |
|
|
(162 |
) |
|
|
616 |
|
|
|
92 |
|
|
|
609 |
|
Depreciation and
amortization |
|
|
1,081 |
|
|
|
1,305 |
|
|
|
3,293 |
|
|
|
3,756 |
|
Stock-based compensation
expense |
|
|
551 |
|
|
|
536 |
|
|
|
1,552 |
|
|
|
1,602 |
|
Gain on forgiveness of
government assistance loans |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(2,775 |
) |
Inventory provision (1) |
|
|
1,388 |
|
|
|
— |
|
|
|
1,388 |
|
|
|
— |
|
Other adjustments (2) |
|
|
726 |
|
|
|
188 |
|
|
|
726 |
|
|
|
188 |
|
Adjusted EBITDA |
|
$ |
(7,679 |
) |
|
$ |
(3,548 |
) |
|
$ |
(19,028 |
) |
|
$ |
(8,116 |
) |
(1) For the three and nine months ended September 30, 2022, the
inventory provision represents a strategic review of our product
offerings which culminated in a decision to discontinue production
and sale of certain models and component parts, resulting in an
inventory adjustment of $1.4 million.
(2) For the three and nine months ended September 30, 2022, the
other adjustments are represented by severance payments associated
with a workforce reduction in Venus Spain and Venus Canada of $0.7
million. For the three and nine months ended September 30, 2021,
the other adjustments are represented by a loss on the sale of a
subsidiary in South Africa ($0.2 and $0.2 million,
respectively).
Investor Relations Contact:
ICR Westwicke on behalf of Venus Concept:
Mike Piccinino, CFA
VenusConceptIR@westwicke.com
Venus Concept (NASDAQ:VERO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Venus Concept (NASDAQ:VERO)
Historical Stock Chart
From Apr 2023 to Apr 2024